

OIPE

RAW SEQUENCE LISTING

DATE: 04/25/2001

PATENT APPLICATION: US/09/825,242

TIME: 13:49:23

Input Set : N:\Crf3\RULE60\09825242.txt

Output Set: N:\CRF3\04252001\I825242.raw

3 <110> APPLICANT: Schenk, Dale B.
 4 Neuralab Limited
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
 8 <130> FILE REFERENCE: 15270J-004720US
 10 <140> CURRENT APPLICATION NUMBER: 09/825,242
 11 <141> CURRENT FILING DATE: 2001-04-02
 13 <150> PRIOR APPLICATION NUMBER: 09/201,430
 14 <151> PRIOR FILING DATE: 1998-11-30
 16 <150> PRIOR APPLICATION NUMBER: US 60/080,970
 17 <151> PRIOR FILING DATE: 1998-04-07
 19 <160> NUMBER OF SEQ ID NOS: 5
 21 <170> SOFTWARE: PatentIn Ver. 2.1
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 42
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Homo sapiens
 28 <220> FEATURE:
 29 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide
 31 <400> SEQUENCE: 1
 32 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 33 1 5 10 15
 35 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 36 20 25 30
 38 Gly Leu Met Val Gly Gly Val Val Ile Ala
 39 35 40
 42 <210> SEQ ID NO: 2
 43 <211> LENGTH: 13
 44 <212> TYPE: PRT
 45 <213> ORGANISM: Artificial Sequence
 47 <220> FEATURE:
 48 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-12
 49 peptide with carboxyl terminal Cys residue
 50 inserted
 52 <400> SEQUENCE: 2
 53 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
 54 1 5 10
 57 <210> SEQ ID NO: 3
 58 <211> LENGTH: 6
 59 <212> TYPE: PRT
 60 <213> ORGANISM: Artificial Sequence
 62 <220> FEATURE:
 63 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta1-5
 64 peptide with carboxyl terminal Cys residue
 65 inserted
 67 <400> SEQUENCE: 3
 68 Asp Ala Glu Phe Arg Cys
 69 1 5

ENTERED

Entered from empiric CRF, converted in Paper 3

RAW SEQUENCE LISTING

DATE: 04/25/2001

PATENT APPLICATION: US/09/825,242

TIME: 13:49:23

Input Set : N:\Crf3\RULE60\09825242.txt

Output Set: N:\CRF3\04252001\I825242.raw

```

72 <210> SEQ ID NO: 4
73 <211> LENGTH: 12
74 <212> TYPE: PRT
75 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta33-42
79     peptide with carboxyl terminal Cys residue
80     inserted
82 <220> FEATURE:
83 <221> NAME/KEY: MOD_RES
84 <222> LOCATION: (2)
85 <223> OTHER INFORMATION: Xaa = amino hepatanoic acid
87 <400> SEQUENCE: 4
W--> 88 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
      89   1           5           10
92 <210> SEQ ID NO: 5
93 <211> LENGTH: 19
94 <212> TYPE: PRT
95 <213> ORGANISM: Artificial Sequence
97 <220> FEATURE:
98 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
99     peptide with carboxyl terminal Cys residue
100     inserted and two added Gly residues
102 <220> FEATURE:
103 <221> NAME/KEY: MOD_RES
104 <222> LOCATION: (1)
105 <223> OTHER INFORMATION: Xaa = acetyl histidine
107 <400> SEQUENCE: 5
W--> 108 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
      109   1           5           10           15
111 Gly Gly Cys

```

VERIFICATION SUMMARY DATE: 04/25/2001
PATENT APPLICATION: US/09/825,242 TIME: 13:49:24

Input Set : N:\Crf3\RULE60\09825242.txt
Output Set: N:\CRF3\04252001\I825242.raw

L:88 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5